BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "In-Line" Rating at Evercore ISI

Key Points

• Evercore ISI has reaffirmed an "in-line" rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) with a price target of $8.00, indicating a potential upside of 5.40% from the current stock price.
• BioCryst reported a strong quarterly earnings with $0.15 EPS, significantly beating analysts' expectations and achieving a revenue increase of 49.5% compared to the same quarter last year.
• Overall, eight investment analysts have rated BioCryst with a "Buy," while two have issued a "Hold," leading to a consensus rating of "Moderate Buy" and an average target price of $16.30.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "in-line" rating reiterated by stock analysts at Evercore ISI in a note issued to investors on Wednesday, Marketbeat Ratings reports. They currently have a $8.00 price target on the biotechnology company's stock. Evercore ISI's target price suggests a potential upside of 5.40% from the company's current price.

A number of other brokerages have also commented on BCRX. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 26th. Bank of America lifted their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Tuesday, July 1st. Royal Bank Of Canada reiterated an "outperform" rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Needham & Company LLC reiterated a "buy" rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Finally, Wedbush lifted their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, June 30th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $16.30.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.59 on Wednesday. BioCryst Pharmaceuticals has a twelve month low of $6.01 and a twelve month high of $11.31. The firm has a market cap of $1.59 billion, a PE ratio of -42.16, a price-to-earnings-growth ratio of 1.52 and a beta of 1.13. The business has a fifty day moving average of $8.19 and a 200-day moving average of $8.71.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. BioCryst Pharmaceuticals's revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.06) earnings per share. On average, analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the firm's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at approximately $556,145.52. This trade represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.10% of the company's stock.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. State Street Corp lifted its holdings in shares of BioCryst Pharmaceuticals by 8.9% during the 2nd quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company's stock valued at $76,208,000 after purchasing an additional 691,988 shares in the last quarter. Alkeon Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 1.7% during the 1st quarter. Alkeon Capital Management LLC now owns 7,214,021 shares of the biotechnology company's stock valued at $54,105,000 after purchasing an additional 120,199 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company's stock valued at $45,296,000 after purchasing an additional 93,973 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of BioCryst Pharmaceuticals by 2,103.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company's stock valued at $38,336,000 after purchasing an additional 4,084,403 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 382.6% during the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock valued at $28,597,000 after purchasing an additional 3,022,769 shares in the last quarter. Institutional investors own 85.88% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.